Catheter-related thrombosis is one of the late complications of totally implantable venous access port. Until now, few studies have introduced the practice of totally implantable venous access port in the clinical setting. On the basis of an extensive literature review, this chapter describes the definitions of various central venous catheter-related thrombosis, thrombogenic mechanism, clinical manifestations of thrombosis, diagnosis, prevention and treatment. The different incidence, catheter inserting technique, clinical presentations and treatment between adults and children are also demonstrated. The diagram, table and photographs from clinical cases are used to directly illustrate one of the most common complication of central venous access. The summary of both basic and clinical studies may help or serve as a guidance to provide clinical care for those in need of totally implantable venous access devices.


Central venous catheter Totally implantable venous access device Thrombosis Sleeve thrombus Fibrin sheaths Deep venous thrombosis Thrombolytic agents Anticoagulant Heparin Venography 


  1. 1.
    DeBona R (1999) Thrombotic complications of central venous catheters in cancer patients. Semin Thromb Hemost 25:147–155CrossRefGoogle Scholar
  2. 2.
    Lokich JJ, Bothe A, Benotti P et al (1985) Complications and management of implanted venous access catheters. J Clin Oncol 3:710–717PubMedGoogle Scholar
  3. 3.
    Hoch JR (1997) Management of the complications of long-term venous access. Semin Vasc Surg 10:135–143PubMedGoogle Scholar
  4. 4.
    Martin C, Viviand X, Saux P et al (1999) Upper extremity deep vein thrombosis after central venous catheterization via the axillary vein. Crit Care Med 27:2626–2629PubMedCrossRefGoogle Scholar
  5. 5.
    Xiang DZ, Verbeken EK, Van Lommel AT et al (1998) Composition and formation of the sleeve enveloping a central venous catheter. J Vasc Surg 28:260–271PubMedCrossRefGoogle Scholar
  6. 6.
    Ruesch S, Walder B, Tramer MR (2002) Complications of central venous catheters: Internal jugular versus subclavian access—A systematic review. Crit Care Med 30:454–460PubMedCrossRefGoogle Scholar
  7. 7.
    Zhang Qinming, Jiao Lii, Zhou Hong (2009) Comparison of implantable central venous ports with catheter insertion via external jugular cut down and subclavian puncture in children: single center experience. Pediatr Surg Int 25:499–501CrossRefGoogle Scholar
  8. 8.
    Horattas MC, Wright DJ, Fenton AH et al (1998) Changing concepts of deep venous thrombosis of the upper extremity-Report of series and review of the literature. Surgery 104:561–567Google Scholar
  9. 9.
    Brismar BO, Hardstedt C, Jacobson S (1981) Diagnosis of thrombosis by catheter phlebography after prolonged central venous catheterisation. Ann Surg 194:779–783PubMedCrossRefGoogle Scholar
  10. 10.
    Pierce CM, Wade A, Mok Q (2000) Heparin-bonded central venous lines reduce thrombotic and infective complications in critically ill children. Intensive Care Med 26:967–972PubMedCrossRefGoogle Scholar
  11. 11.
    De Cicco M, Matovic M, Balestrieri L et al (1997) Central venous thrombosis: An early and frequent complication in cancer patients bearing long term silastic catheter—A prospective study. Thromb Res 86:101–113PubMedCrossRefGoogle Scholar
  12. 12.
    Horattas MC, Wright DJ, Fenton AH et al (1988) Changing concepts of deep venous thrombosis of the upper extremity—report of a series and review of the literature. Surgery 104:561–567PubMedGoogle Scholar
  13. 13.
    Bern HM, Lokich JJ, Wallach SR et al (1990) Very low dose of warfarin can prevent thrombosis in central venous catheters: A randomized, prospective trial. Ann Inter Med 112:423–428Google Scholar
  14. 14.
    Monreal M, Alastrue A, Rull M et al (1996) Upper extremity deep venous thrombosis in cancer patients with venous access devices: Prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 75:251–253PubMedGoogle Scholar
  15. 15.
    Massicotte P, Julian JA, Gent M et al (2003) An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line related thrombotic complications in children: The PROTEKT study. Thromb Res 109:101–108PubMedCrossRefGoogle Scholar
  16. 16.
    Reichardt P, Kretzschmar A, Biakhov M et al (2002) A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of daily low-molecular-weightheparin (dalteparin sodium) in preventing catheter-related complications (CRCs) in cancer patients with central venous catheters (CVCs). Proc Am Soc Clin Oncol 21:369a (abstr 1474)Google Scholar
  17. 17.
    Mismetti P, Mille D, Laporte S et al (2003) Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: A pilot randomized trial. Haematologica 88:67–73PubMedGoogle Scholar
  18. 18.
    Raaf JH (1985) Results from the use of 826 vascular access devices in cancer patients. Cancer 55:1312–1321PubMedCrossRefGoogle Scholar
  19. 19.
    Hurtubise MR, Bottino JC, Lawson M et al (1980) Restoring patency of occluded central venous catheters. Arch Surg 115:212–213PubMedCrossRefGoogle Scholar
  20. 20.
    William DH, Robert PL (1992) Thrombosed central venous catheters: Restoring function with 6-hour urokinase infusion after failure of bolus urokinase. JPEN J Parenter Enteral Nutr 16:129–132CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2012

Authors and Affiliations

  1. 1.Pediatric SurgeryBeijing Children’s Hospital affiliated to Capital University of MedicineBeijingChina

Personalised recommendations